# Pre-approval Expanded Access of Retatrutide (LY3437943)

> **NCT07629401** · — · AVAILABLE · sponsor: **Eli Lilly and Company**

## Conditions studied

- Obesity
- Obesity-related Complications

## Interventions

- **DRUG:** Retatrutide

## Key facts

- **NCT ID:** NCT07629401
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629401, "Pre-approval Expanded Access of Retatrutide (LY3437943)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*